A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid‐Reducing Agents
- 28 February 2019
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 59 (8), 1093-1098
- https://doi.org/10.1002/jcph.1399
Abstract
Doravirine is a novel non‐nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus type 1 infection. Because of potential concomitant administration with acid‐reducing agents, a drug‐interaction trial was conducted to evaluate the potential impact of these types of medications on doravirine pharmacokinetics. In an open‐label, 3‐period, fixed‐sequence trial, healthy adult participants received the following: period 1, a single dose of doravirine 100 mg; period 2, coadministration of a single dose of doravirine 100 mg and an antacid (1600 mg aluminum hydroxide, 1600 mg magnesium hydroxide, and 160 mg simethicone); period 3, 40 mg pantoprazole once daily on days 1–5 coadministered with a single dose of doravirine 100 mg on day 5. There was a minimum 10‐day washout between periods. Plasma samples for pharmacokinetic evaluation were collected, and safety was assessed. Fourteen participants (8 male, 6 female) were enrolled, and 13 completed the trial. Geometric mean ratios (90% confidence intervals) for doravirine AUC0‐inf, Cmax, and C24 for doravirine + antacid/doravirine were 1.01 (0.92–1.11), 0.86 (0.74–1.01), and 1.03 (0.94–1.12), respectively, and for doravirine + pantoprazole/doravirine were 0.83 (0.76–0.91), 0.88 (0.76–1.01), and 0.84 (0.77–0.92), respectively. Doravirine was generally well tolerated administered alone or with either of the acid‐reducing agents. Coadministration of an aluminum/magnesium‐containing antacid or pantoprazole did not have a clinically meaningful effect on doravirine pharmacokinetics, supporting the use of acid‐reducing agents with doravirine.Keywords
Funding Information
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey
This publication has 16 references indexed in Scilit:
- Characterizing Class‐Specific Exposure‐Viral Load Suppression Response of HIV Antiretrovirals Using A Model‐Based Meta‐AnalysisClinical and Translational Science, 2016
- A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individualsAIDS, 2016
- Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohortInternational Journal of STD & AIDS, 2015
- Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patientsJournal of the International AIDS Society, 2014
- Managing drug interactions in HIV-infected adults with comorbid illnessCMAJ : Canadian Medical Association Journal, 2014
- Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV virusesBioorganic & Medicinal Chemistry Letters, 2014
- Probing chelation motifs in HIV integrase inhibitorsProceedings of the National Academy of Sciences, 2012
- Concomitant use of gastric acid‐reducing agents is frequent among HIV‐1‐infected patients receiving protease inhibitor‐based highly active antiretroviral therapy*HIV Medicine, 2007
- Pantoprazole versus omeprazoleEuropean Journal of Gastroenterology & Hepatology, 1999
- Antacids RevisitedDrugs, 1999